Search Results
Jun 06, 2026, 14:30 ET Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
(19.0%).3 Notably, 65.3% of participants on retatrutide 12 mg achieved a BMI <30, and 33.3% reached a BMI <25, representing healthy BMI. In a pre-specified extension for participants with baseline BMI ≥35, those continuing on retatrutide 12 mg through 104 weeks lost an average of 85.0
More news about: Eli Lilly and Company
Jun 06, 2026, 14:30 ET Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
medications. The randomized, double-blind, placebo-controlled trial included 537 participants with recent-onset type 2 diabetes (mean 2.5 years) and a BMI of ≥23 kg/m². Over 40 weeks, participants were randomly assigned to receive a once-weekly injection of 4 mg, 9 mg, or 12 mg of retatrutide, or placebo.Findings
More news about: American Diabetes Association
Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
plasma glucose, and hsCRP) by baseline BMI class, patients with overweight/obesity class I (BMI 27-<35, n=85) treated with semaglutide tablets 25 mg had similar or greater improvements in cardiometabolic outcomes compared with the obesity class II/III cohort (BMI >=35, n=119) at week 64.6
More news about: NOVO NORDISK INC.
Jun 05, 2026, 18:37 ET BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Badger Meter, Inc. (NYSE: BMI) between April 18, 2024 and April 16, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead
More news about: THE ROSEN LAW FIRM, P. A.
Jun 05, 2026, 18:30 ET First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
randomized, placebo-controlled study that enrolled 111 adults with type 1 diabetes who were classified as having overweight or obesity (body mass index (BMI) greater than or equal to 27 kg/m²). Participants were randomly assigned to receive acmopatide at doses of 1.8 mg, 4.1 mg, 6.6 mg, or placebo. The study's
More news about: American Diabetes Association
Jun 04, 2026, 11:00 ET Shareholder Alert: Wisconsin Firm Ademi LLP Investigates Claims of Securities Fraud against Badger Meter, Inc.
June 4, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Badger Meter (NYSE: BMI). The investigation results from inaccurate statements Badger Meter may have made regarding its financial statements, business operations and prospects.
More news about: Ademi LLP
Jun 04, 2026, 09:00 ET SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in Badger Meter, Inc. Lawsuit - BMI
aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.Frequently Asked Questions About the BMI LawsuitQ: What specific misstatements does the BMI lawsuit allege? A: The complaint alleges Badger Meter made materially false or misleading
More news about: SueWallSt.com
Jun 04, 2026, 06:40 ET Roofing Membranes Market worth $39.78 billion by 2031 - Exclusive Report by MarketsandMarkets™
the report include SIKA AG (Switzerland), GAF Materials LLC (US), Soprema (France), Johns MANVILLE (US), Carlisle Companies Inc (US), ELEVATE (US), BMI group and (UK), Bauder (Germany), SIPLAST (US), IKO Industries Itd (Canada).ISOMAT (Greece), JUTA Ltd (UK), Kemper System (Germany) are a few
More news about: MarketsandMarkets
Jun 03, 2026, 19:14 ET BMI Investor Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Badger Meter, Inc.
LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Badger Meter, Inc. (NYSE: BMI) common stock between April 18, 2024 and April 16, 2026. Badger Meter manufactures and sells water measurement and management products.
More news about: Robbins LLP
Jun 03, 2026, 18:21 ET Levi & Korsinsky Reminds Badger Meter, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 3, 2026 - BMI
the complaint, the market punished BMI with another $18.09 per share decline. The April 2026 disclosure was the sharpest inflection point: total sales fell 9% year-over-year, utility water sales dropped 10%, and operating margins contracted from 22.2% to 17.4%. BMI lost $36.75 per share, more than 24%,
More news about: Levi & Korsinsky, LLP
Jun 03, 2026, 08:36 ET JOMS Study Links Obesity to Higher Risk of Dental Implant Complications
mass index (BMI), a standard measure used to categorize weight. Over a five-year follow-up period, researchers tracked which patients developed peri-implantitis, one of the most serious complications associated with dental implant therapy.The results were clear: patients with a BMI of 30 or higher
More news about: AAOMS/Journal of Oral and Maxillofacial Surgery
Jun 02, 2026, 08:00 ET The Scale Built for the GLP-1 Era
stronger, healthier body.NEW Withings BodyFit Coaches You. No Logging, No Guesswork: Most scales stop at just providing weight & BMI data. BodyFit turns a simple weight goal into a personalized body composition journey, automatically tracking calorie balance and generating habit-based
More news about: Withings
Jun 02, 2026, 06:41 ET BMI Stock Drop: Badger Meter Investigated for Securities Fraud after Stock Plummets 24% on Product Demand Issues
Bleichmar Fonti & Auld LLP announces an investigation into Badger Meter, Inc. (NYSE: BMI) for potential securities fraud after significant stock drops.
More news about: Bleichmar Fonti & Auld LLP
May 27, 2026, 09:00 ET Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions
STEP and OASIS Programs – Sunday, June 7; 12:30–1:30 pm CDT2838-LB Cardiometabolic Effects of Semaglutide in OASIS 4 Participants by BMI Class – Sunday, June 7; 12:30–1:30 pm CDT1685-P Exploring Semaglutide's Effect on the ASCVD-Related Proteomic Signature and Their Prediction
More news about: NOVO NORDISK INC.
May 27, 2026, 08:00 ET BMI Imaging's "The Digital Imaging Channel" Surpasses 160,000 Views on YouTube
system workflows.To learn more about BMI Imaging's secure digitization and hosting solutions, visit https://www.bmiimaging.com.About BMI Imaging SystemsFounded in 1958, BMI Imaging Systems helps organizations convert
More news about: BMI Imaging Systems, Inc.
May 26, 2026, 06:16 ET BMI Notification: Badger Meter Product Demand Issues and Corresponding 24% Stock Drop Trigger Shareholder Investigation for Securities Fraud
multimedia:https://www.prnewswire.com/news-releases/bmi-notification-badger-meter-product-demand-issues-and-corresponding-24-stock-drop-trigger-shareholder-investigation-for-securities-fraud-302780400.htmlSOURCE
More news about: Bleichmar Fonti & Auld LLP
May 22, 2026, 06:02 ET 14 Press Releases You Need to See This Week
(28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric surgery. Individuals with a baseline BMI ≥35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks.
More news about: PR Newswire
May 21, 2026, 15:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Badger Meter, Inc. - BMI
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Badger Meter, Inc. ("Badger Meter" or the "Company") (NYSE: BMI). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 21, 2026, 06:45 ET Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
participants taking retatrutide 12 mg achieved a BMI <30, falling under the threshold for obesity at 80 weeks, including 37.5% of those who started with class 3 obesity (BMI ≥40).1 In a pre-specified blinded extension for those with a BMI ≥35, participants who continued on retatrutide 12
More news about: Eli Lilly and Company
May 20, 2026, 08:00 ET BMI Exhibits at AACRAO 2026, Continuing Support for Higher Education Records Modernization
https://www.bmiimaging.com.About BMI Imaging SystemsFounded in 1958, BMI Imaging Systems helps organizations convert paper, microfilm, and microfiche into secure, searchable digital collections. BMI provides public, private, and CJIS-compliant hosting solutions
More news about: BMI Imaging Systems, Inc.
May 19, 2026, 15:46 ET BMI Stock Alert: Badger Meter Investors with Losses are Notified of the Pending Securities Fraud Investigation Over Demand Issues
multimedia:https://www.prnewswire.com/news-releases/bmi-stock-alert-badger-meter-investors-with-losses-are-notified-of-the-pending-securities-fraud-investigation-over-demand-issues-302776708.htmlSOURCE
More news about: Bleichmar Fonti & Auld LLP
May 14, 2026, 20:15 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Badger Meter, Inc. - BMI
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Badger Meter, Inc. ("Badger Meter" or the "Company") (NYSE: BMI). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 12, 2026, 23:33 ET WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
long-term economic, environmental and social performance, selecting from the largest 2,500 global companies in the S&P Global Broad Market Index (BMI) and from the largest 800 companies across 20 emerging markets, respectively.Based on the 2025 CSA, WuXi Biologics ranked among the top 1% globally
More news about: WuXi Biologics
May 12, 2026, 07:05 ET Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
cohort = 30 mg x 2 weeks, 60 mg x 2 weeks, 90 mg x 2 weeks, 120 mg x 7 weeks. 3) All enrolled participants were required to have baseline BMI ≥30 kg/m2 or BMI≥27 kg/m2 with at least one weight-related comorbid condition. 4) Least squares mean. 5) Two-sided t-test using mixed model for
More news about: Viking Therapeutics, Inc.
May 11, 2026, 14:12 ET Weight Management Market to Reach USD 381.5 Billion, Globally, by 2033 at 10.3% CAGR: Allied Market Research
period. In the United States specifically, this dominance is driven by an obesity epidemic at critical levels over 40% of adults are categorized by BMI as having obesity according to CDC data. The area is staffed with robust healthcare infrastructure, high penetration for covering obesity-related injunctive
More news about: Allied Market Research